Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3, 2000, Pages 281-289

  Van Guldener, C ^a   Stehouwer, C D A ^a  

^a NONE   (Netherlands)

Author keywords

Atherothrombosis; Endothelial function; Hyperhomocysteinemia; Treatment; Vascular diseases

Indexed keywords

HOMOCYSTEINE; NITRIC OXIDE;

ANGIOCARDIOGRAPHY; ARTERY DILATATION; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; DISEASE ASSOCIATION; ENDOTHELIUM LESION; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ADULT; ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CAROTID STENOSIS; CHILD; COMORBIDITY; CORONARY ANGIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTINURIA; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERPLASIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; METHIONINE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; OXIDATIVE STRESS; PREVALENCE; RABBITS; RATS; VASODILATION;

EID: 0033817681     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
2. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease
3. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
4. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
5. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project
6. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
7. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine
8. Membrane protein damage and methylation reactions in chronic renal failure
9. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
10. Pathological findings in homocystinuria
11. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis
12. Production of arteriosclerosis by homocysteinemia
13. Experimental homocysteinemia in pigs: Comparison with studies in sixteen homocystinuric patients
14. Homocysteine thiolactone and experimental homocysteinemia
15. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine
16. Homocysteine theory of arteriosclerosis
17. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations
18. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease
19. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men
20. Plasma homocysteine levels and mortality in patients with coronary artery disease
21. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis
22. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease
23. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis
24. Homocysteine in cerebral macroangiopathy and microangiopathy
25. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease
26. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis
27. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia
28. Hyperhomocysteinaemia: A risk factor for extracranial carotid artery atherosclerosis
29. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study
30. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults
31. Premature carotid atherosclerosis: Does it occur in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of arterial intima-media thickness and blood flow velocity
32. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-beta-synthase deficiency
33. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects
34. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia
35. Evidence of carotid artery wall hypertrophy in homozygous homocystinuria
36. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study
37. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)
38. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area
39. The reaction of homocysteine with aldehyde: An explanation of the collagen defects in homocystinuria
40. A collagen defect in homocystinuria
41. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans
42. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
43. Familial hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries
44. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients
45. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease
46. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
47. Homocysteine increases cyclin-dependent kinase in aortic rat tissue
48. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells
49. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty
50. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury
51. The pathogenesis of atherosclerosis: A perspective for the 1990s
52. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury
53. Human arterial endothelial cell detachment in vitro: Its promotion by homocysteine and cysteine
54. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine
55. Homocysteine mediated endothelial cell toxicity and its amelioration
56. Endothelial cell damage and homocysteine
57. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
58. Lipid peroxidation and homocysteine induced toxicity
59. Oxidation of low density lipoprotein by thiols: Superoxide-dependent and -independent mechanisms
60. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: A possible role for hydrogen peroxide
61. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
62. Stimulation of endothelial nitric oxide production by homocyst(e)ine
63. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents
64. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
65. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2
66. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells
67. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation of pancreatic vascular bed in rats
68. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia
69. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
70. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide
71. Close relation of endothelial function in the human coronary and peripheral circulations
72. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease
73. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients
74. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis
75. Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor, but not with endothelium-dependent vasodilatation in healthy postmenopausal women
76. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults
77. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia - An effect reversible with vitamin C therapy
78. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid
79. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
80. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
81. Low concentrations of folate in serum and erythrocytes of smokers - Methionine loading decreases folate concentrations in serum of smokers and nonsmokers
82. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins
83. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation
84. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys
85. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients
86. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
87. Effects of folate supplementation in hyperhomocysteinemic pigs
88. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
89. The natural history of homocystinuria due to cystathionine beta-synthase deficiency
90. Hyperhomocysteinemia - A risk factor for ischemic stroke in children
91. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men - A 10-year follow-up